Accelerated Immunosenescence and Chronic Kidney Disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Renal Failure
- Sponsor
- Centre Hospitalier Universitaire de Besancon
- Enrollment
- 222
- Locations
- 1
- Primary Endpoint
- Percentage of Cluster of Differentiation (CD) 4/8+ CD 57+ CD 28- lymphocytes (senescent lymphocytes)
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The aim of this study is to investigate the impact of renal function and dialysis techniques on the percentage of senescent T lymphocytes.
Detailed Description
The immunosenescence is a complex and profound remodeling of the immune system during life. It is mainly due to thymic involution and repeated antigenic stimulation. Kidney disease is associated with a decrease in adaptive immunity as evidenced by the decrease in vaccine response and increased susceptibility to infections, similar to those observed in the elderly population. However, data on aging of the immune system in chronic kidney disease remains incomplete. Furthermore, the determinants of immunosenescence are not also not known. It is possible that "uremic" factors help explain the phenotypic and functional changes of lymphocytes, as antigenic stimuli associated with repeated bio-compatible materials used in dialysis contact. The purpose of this study is to describe the phenotypes of the immune system of renal and analyze the determinants of these changes.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient able to understand the reason of the study
- •Patient not opposed to the conservation of biological samples for scientific research
Exclusion Criteria
- •Patient suffering from psychotic illness
- •Any history of immunosuppressive therapy (except steroids up to 5mg/day)
- •History of cancer (except skin cancer) or treated hematological malignancy
- •Infectious episode required hospitalization not older 3 months
- •Hepatitis B or C infection
- •HIV infection, active or inactive
- •For dialysis patients: renal failure on dialysis for less than 3 months and/or have benefited from two techniques for renal replacement therapy in the last 6 months
Outcomes
Primary Outcomes
Percentage of Cluster of Differentiation (CD) 4/8+ CD 57+ CD 28- lymphocytes (senescent lymphocytes)
Time Frame: 6 months
The primary outcome measure is the percentage of CD 4/8+ CD 57+ CD 28- lymphocytes by flow cytometry. The technique used is a 6 colors surface labelling of T lymphocytes to study the T cell senescent population.
Secondary Outcomes
- Level of phospho-histone 2AX (gH2AX) in peripheral blood T lymphocytes(6 months)
- T-cell receptor excision circle (TREC) level in PBMC.(6 months)
- Telomerase Activity of T lymphocytes(6 months)
- Telomere length in T lymphocytes(6 months)
- Proportion of Recent Thymic Emigrants (RTE) in peripheral blood T lymphocytes(6 months)